Agreement with BioView to develop a CTC-based HER2 assay First phase expected to generate c. £1.2 million revenue GUILDFORD, UK / ACCESSWIRE / April 19, 2023 / ANGLE plc (AIM:AGL), (OTCQX:ANPCY), a ...
ANGLE (OTCQX:ANPCY) signs an agreement with BioView to develop a liquid biopsy circulating tumor cell (or CTC) HER2 assay for breast cancer. It will be utilising ANGLE's FDA cleared Parsortix PC1 ...
This development is based on a press release statement and represents an ongoing effort to enhance cancer diagnostics through less invasive methods, with the potential to impact treatment strategies ...
BioView and ScreenCell inked a commercial collaboration that will apply BioView’s Automated Cell Imaging Systems to image circulating tumor cells (CTCs) isolated using ScreenCell’s CytoKit® platform.
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce it has signed an agreement with BioView Ltd. ("BioView") (BIOV.TA) to develop a liquid biopsy ...
BioView President and CEO, Dr. Alan Schwebel, commented: "We are excited for this development partnership opportunity with ANGLE, where we plan to leverage the strengths of both our technologies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results